EWS & EVENTS
Shattuck Labs, Inc. Announces Initiation of Phase 1 Clinical Trial of SL-279252 (PD1/OX40L)

Shattuck Labs Press Release May 6, 2019  

Shattuck Labs Press Release May 6, 2019  
MIGHT ALSO LIKE
YOU MIGHT ALSO LIKE
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (TIM3-Fc-OX40L and TIM3-Fc-CD40L), for Cancer Immunotherapy

SITC 2018

Read more
Takeda and Shattuck Labs Announce Collaboration to Explore ARC Fusion Proteins in Immuno-Oncology

Press Release 2017

Read more